Stocks › AVXL

ANAVEX LIFE SCIENCES CORP.

AVXL·Nasdaq·United States United States·USD
$0.59
-0.08 (-11.39%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
AVXL
ANAVEX LIFE SCIENCES CORP. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
AVXLS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of AVXL by members of U.S. Congress · 2 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Christopher L. JacobsChristopher L. JacobsHouse · R · NY AVXLANAVEX LIFE SCIENCES CORP. · Stock Sale
$1,001 - $15,000
Jan 20, 2023 Dec 12, 2022 Filing ↗
Christopher L. JacobsChristopher L. JacobsHouse · R · NY AVXLANAVEX LIFE SCIENCES CORP. · Stock Purchase
$1,001 - $15,000
Nov 16, 2022 Oct 12, 2022 Filing ↗

Whale Activity

Position changes in AVXL reported for 2026-09-30 by 189 institutional filers
Increased: 42New: 15Held: 36Decreased: 68Closed: 24No prior filing: 4
  • Increased42
  • New15
  • Held36
  • Decreased68
  • Closed24
  • No prior filing4
FilerSharesValueChange
BlackRock, Inc.8.1M$16.5Mincreased
VANGUARD CAPITAL MANAGEMENT LLC4.1M$8.3Mincreased
GMT CAPITAL CORP2.7M$5.5Mnew
FEDERATED HERMES, INC.2.6M$5.2Mincreased
TWO SIGMA INVESTMENTS, LP2.3M$4.7Mdecreased
GEODE CAPITAL MANAGEMENT, LLC2.3M$4.6Mdecreased
STATE STREET CORP2.0M$4.0Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC898.5K$1.8Mdecreased
Summit Financial, LLC889.1K$1.8Mdecreased
GOLDMAN SACHS GROUP INC889.1K$1.8Mdecreased
CHARLES SCHWAB INVESTMENT MANAGEMENT INC887.0K$1.8Mincreased
BARCLAYS PLC868.3K$1.8Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by AVXL insiders, by quarter · Form 4

No open-market insider buys or sells in the last two years.

Recent Insider Transactions

96 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
MISSLING CHRISTOPHER UPresident and CEO · Director Tax withholding −145.0K $9.58 $1.4M Sep 11, 2025 Form 4 ↗
MISSLING CHRISTOPHER UPresident and CEO · Director Option exercise +187.5K $5.04 $945K Sep 11, 2025 Form 4 ↗
Thomas SteffenDirector Tax withholding −11.3K $7.75 $88K Jun 5, 2025 Form 4 ↗
Thomas SteffenDirector Option exercise +50.0K $1.76 $88K Jun 5, 2025 Form 4 ↗
MISSLING CHRISTOPHER UPresident and CEO · Director Tax withholding −282.5K $9.63 $2.7M Mar 24, 2025 Form 4 ↗
MISSLING CHRISTOPHER UPresident and CEO · Director Option exercise +500.0K $0.92 $460K Mar 24, 2025 Form 4 ↗
Donhauser Peter D.O.Director Purchase +2,835 $3.64 $10K Jun 14, 2024 Form 4 ↗
Thomas SteffenDirector Purchase +5,000 $4.52 $23K May 15, 2024 Form 4 ↗
MISSLING CHRISTOPHER UPresident and CEO · Director Sale −73.4K $5.11 $375K Mar 28, 2024 Form 4 ↗
MISSLING CHRISTOPHER UPresident and CEO · Director Option exercise +73.4K $1.32 $97K Mar 28, 2024 Form 4 ↗
MISSLING CHRISTOPHER UPresident and CEO · Director Option exercise +232.0K $1.60 $371K Jun 29, 2023 Form 4 ↗
MISSLING CHRISTOPHER UPresident and CEO · Director Sale −268.0K $7.98 $2.1M Jun 28, 2023 Form 4 ↗
MISSLING CHRISTOPHER UPresident and CEO · Director Option exercise +268.0K $1.60 $429K Jun 28, 2023 Form 4 ↗
Skarpelos AthanasiosDirector Sale −50.0K $9.06 $453K May 25, 2022 Form 4 ↗
Skarpelos AthanasiosDirector Option exercise +50.0K $0.92 $46K May 25, 2022 Form 4 ↗
MISSLING CHRISTOPHER UPresident and CEO · Director Sale −51.6K $26.00 $1.3M Jun 29, 2021 Form 4 ↗
MISSLING CHRISTOPHER UPresident and CEO · Director Option exercise +51.6K $1.32 $68K Jun 29, 2021 Form 4 ↗
Boenisch SandraPFO and Treasurer Sale −166.7K $26.53 $4.4M Jun 29, 2021 Form 4 ↗
Boenisch SandraPFO and Treasurer Option exercise +35.0K $5.92 $207K Jun 29, 2021 Form 4 ↗
Boenisch SandraPFO and Treasurer Option exercise +106.7K $3.28 $350K Jun 29, 2021 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding AVXL · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
2.9M$7.6M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
2.4M$6.3M0.01%Jun 30, 2026
Federated Hermes MDT Small Cap Core Fund
Federated Hermes MDT Series
2.0M$5.6M0.25%Jul 31, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
1.0M$2.8M0.01%Jul 31, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.0M$2.7M0.00%Jun 30, 2026
iShares Russell 2000 Value ETF
iShares Trust
737.5K$1.9M0.01%Jun 30, 2026
iShares Biotechnology ETF
iShares Trust
631.7K$1.6M0.02%Jun 30, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
528.0K$1.5M0.01%Aug 31, 2026
Schwab U.S. Small-Cap ETF
SCHWAB STRATEGIC TRUST
436.3K$1.2M0.01%Aug 31, 2026
Fidelity Extended Market Index Fund
Fidelity Concord Street Trust
398.0K$1.1M0.00%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list AVXL's shares (CUSIP 032797300), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 4.7M shares5.0%
    Jul 31, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming anavex life sciences as client
$0$63K$125K$188K$250K2025 Q1: $60K2025 Q2: $60K2025 Q3: $60K2025 Q4: $60K20252026 Q1: $40K2026
  • FORBES-TATEANAVEX LIFE SCIENCES · 2026 Q1—
    Filing ↗
  • FORBES-TATEANAVEX LIFE SCIENCES · 2026 Q1 · HCR$40K
    Filing ↗
  • FORBES-TATEANAVEX LIFE SCIENCES · 2025 Q4 · HCR$60K
    Filing ↗
  • FORBES-TATEANAVEX LIFE SCIENCES · 2025 Q3 · HCR$60K
    Filing ↗
  • FORBES-TATEANAVEX LIFE SCIENCES · 2025 Q2 · HCR$60K
    Filing ↗

Government Contracts

Federal awards to ANAVEX LIFE SCIENCES CORP. · USAspending

No federal contract awards found for ANAVEX LIFE SCIENCES CORP..

U.S. Patents

Recent USPTO applications naming ANAVEX LIFE SCIENCES CORP.

No USPTO patent applications found for ANAVEX LIFE SCIENCES CORP..

Annual Financials

From AVXL's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Operating income-$51.4M-$52.9M-$55.8M-$51.0M-$42.0M
Net income-$46.4M-$43.0M-$47.5M-$48.0M-$37.9M
Diluted EPS-$0.54-$0.52-$0.60-$0.62-$0.54
Operating cash flow-$39.0M-$30.8M-$27.8M-$24.2M-$30.4M
Cash and equivalents$102.6M$132.2M$151.0M$149.2M$152.1M
Total assets$103.8M$135.6M$154.4M$152.7M$161.6M
Total liabilities$8.9M$15.3M$12.5M$10.2M$10.8M
Shareholders' equity$94.9M$120.3M$141.9M$142.5M$150.8M

As ANAVEX LIFE SCIENCES CORP. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Nov 25, 2025 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-4Reverse splitOct 7, 2015

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 5.02, 9.01Officer / director changeNov 3, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 8.01, 9.01Officer / director change · Other eventsNov 2, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsOct 20, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsOct 15, 2026
    EDGAR ↗
  • 8-K · Items 5.01, 5.07Change in control · Shareholder voteSep 28, 2026
    EDGAR ↗
  • 8-K · Items 8.01Other eventsSep 9, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsSep 2, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 25, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureAug 17, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureAug 11, 2026
    EDGAR ↗

About ANAVEX LIFE SCIENCES CORP.

From SEC EDGAR company records

Overview and Strategy Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (“CNS”) diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our clinical trials. The Company’s focus is on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Our research and development pipeline includes ANAVEX®2-73 currently in thre…

Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersNEW YORK, NY
Former namesThrifty Printing Inc.